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Artigo de Revisão
Abstract: Atopic dermatitis is a chronic inflammatory skin disease with a steadily increasing prevalence
affecting 10-20 % of infants and 1-3% of adults globally.  It is often the first clinical manifestation of atopic
disease preceding asthma and allergic rhinitis.  Probably half of the children with atopic dermatitis devel-
op some other form of atopic disease later in life.  The pathogenesis involves a complex interplay of fac-
tors including genetic predisposition due to altered immune or skin barrier function, interactions with the
environment such as food and allergen exposures, and infectious triggers of inflammation.  In this review,
we summarize the recent advances in understanding the contribution of different factors in the pathophysiology
of atopic dermatitis and how insights provide new therapeutic potential for its treatment.  
Keywords: Asthma; Atopic Dermatitis, Eczema; Eosinophils; Genetics; Immunoglobulin E;
Keratinocytes; Rhinitis, T-Lymphocytes
Resumo: A dermatite atópica é uma doença cutânea inflamatória crônica cuja prevalência tem
aumentado de forma constante, afetando 10-20% dos lactentes e 1-3% dos adultos em todo o mundo.
Ela é freqüentemente a primeira manifestação clínica de doença atópica, precedendo a asma e a
rinite alérgica. Provavelmente metade das crianças com dermatite atópica desenvolvem alguma
outra forma de doença atópica em outras fases da vida. A patogenia envolve uma interação com-
plexa entre fatores que incluem predisposição genética devido a uma função alterada da barreira
cutânea ou imunológica, interações com o ambiente, tais como exposição a alimentos e alergenos,
e desencadeadores infecciosos de inflamação. Nesta revisão, resumimos os avanços recentes na com-
preensão da contribuição de diferentes fatores à fisiopatologia da dermatite atópica e como os
novos conhecimentos proporcionam novo potencial terapêutico. 
Palavras-chave: Asma; Ceratinócitos; Dermatite atópica; Eczema; Eosinófilos; Genética;
Imunoglobulina E; Linfócitos T; Rinite
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INTRODUCTION
In the last 20 to 30 years the prevalence of
atopic dermatitis (AD) has increased dramatically 1-5
attracting the attention of public health, immunology,
allergy and dermatology communities.  The objective
of the current review is to highlight cellular and
molecular mechanisms involved in the pathogenesis
of this disease, as well as to provide an overview of
how this increased understanding can be translated
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into improved therapeutic strategies. 
Atopic dermatitis or atopic eczema is a chronic
inflammatory skin disease with a high incidence in the
first year of life, and while AD can persist into 
childhood, symptoms usually remit by puberty.  Atopic
dermatitis can also be present in adults and affects more
than 10 % of the total population, with 80 to 90 % of
those affected being children under 5 years of age.4
Atopic dermatitis is frequently perceived as a
minor dermatological disorder. However, the high
prevalence of this condition carries financial and
social costs not only for the community, regarding
medical and hospital costs, but also for the patient
and the patient’s family.6 Studies carried out in
Netherlands, England, Australia, United States and
recently in Italy, support the idea that families with
AD-affected children have significantly higher expenses,
that correlate with the severity of the disease. 7-13 In
this regard, the last report published by Ellis et al. in
the United States of America in 2002, estimates the
annual cost to private insurance and Medicaid of AD
illness ranges from $US 0.9 billion to $US 3.8 billion.
This cost is comparable to the cost estimated for other
diseases such as emphysema, psoriasis and epilepsy.8
Atopic dermatitis, regarded as a chronic illness,
can affect a child’s quality of life and has been extensive-
ly addressed in a recent review.14 In this regard, the
chronic nature and severity of the lesions can not only
negatively impact the child, but also primary family
members.  The stress associated with taking care of a
child with AD can be aggravated by disturbed sleeping
patterns, and consequences of its pruritic nature lead
to physical and mental exhaustion, mood changes,
lack of concentration at school or work, as well as
increased parental and child morbidity.12 
As already mentioned, AD is a pruritic disease,
whose diagnosis is based on physician examination,
according to the criteria established by Hanifin-Rafka.15
The clinical pattern associated with AD differs depending
on age (Figure 1 A, B, C).  Mild cases are associated with
erythema in localized areas of the skin. In infants, exudative
lesions are more frequently observed in the cheeks, scalp
and extensor surfaces of the arms and legs.  Chronic skin
inflammation can be further exacerbated by infection.
Older children tend to have lesions in the flexural areas
of the extremities.  Acute lesions may appear as 
erythematous macules or papules.  However, the intense
scratching behavior as a consequence of its pruritic
nature, induces a cycle of chronic/relapsing 
clinical course, inducing remodeling of the skin.
Characteristic features of AD chronic skin lesions are 
dryness as a consequence of transepidermal water loss,
lichenification or thickening and hypertrophy of the 
epidermis, disruption of the skin barrier and 
consequently increased permeability to allergens and
FIGURE 1:  Clinical appearance of atopic dermatitis lesions in
patients. A. Mild atopic dermatitis appears as a localized area of skin
inflammation with erythema and dryness. In a child + parent, B.
Acute skin inflammation exacerbated by infection in a child with
atopic dermatitis, C. Chronic skin inflammation with lichenification
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microbes, as well as an increase in the infiltrate of
mononuclear cells and some eosinophils in the dermis.16
Inflammation results from interactions of
immune cells and keratinocytes.  The complex picture
of the AD lesion is aggravated by environmental and
genetic factors that increase the difficulty of under-
standing the mechanisms behind this complex patho-
physiology (Figure 2).
ATOPIC DERMATITIS AND THE ALLERGIC MARCH
Children with early onset AD are also more likely
to be atopic individuals, defined by positive skin prick
test (SPT) or elevated antigen-specific serum
immunoglobulin E (IgE) against common environmental
or food allergens.17 Moreover, the number of positive
SPT and/or levels of specific IgE are associated with the
severity of the AD disease.18 Fifty to 80% of the children
with AD will develop asthma or allergic rhinitis by 5
years of age. This temporal progression of atopic
symptoms from atopic dermatitis to allergic sensitization
of the skin, food allergy, hay fever (allergic rhinitis) and
later airway hyperresponsivness and airway inflammation
or asthma, has been named the “allergic march”.19-21
The pathogenesis of AD is still unclear.
However, as different disorders seen in the same
patient have specific IgE as a common feature, it
seems that AD could be seen as a local manifestation
of a systemic disease, where specific IgE has a central
role.  This type of AD is called the extrinsic or atopic
form and accounts for 45 to 75% of the individuals.22, 23
However, specific IgE by itself is not a useful
discriminator for AD. Others risk factors such as
maternal history of atopy, ethnicity,24 socioeconomic
status,25 environmental and genetic factors, gender,
and early day care attendance also contribute to the
exacerbation of the eczema, and support the existence
of a second variant, the intrinsic or nonatopic form,
that can also account for up to two thirds of the
eczematous patients.23
SKIN BARRIER DYSFUNCTION
Atopic dermatitis is characterized by dry skin
involving lesional and non-lesional skin, as well as
increased transepidermal water loss (TEWL). The
pathogenesis of AD resulting in dry skin and eczematous
lesions is believed to be as a consequence of a defective
permeability barrier leading to the absorption of 
environmental allergens into the skin.  Defects in the
Clinical correlations of recent developments in the pathogenesis of atopic dermatitis 59
FIGURE 2: Immunological mechanisms involved in atopic dermatitis. Initiation of the atopic response in AD involves the uptake and process-
ing of allergens by LCs after penetration through the compromised epithelial barrier.  The activated LCs then migrate to skin draining LN and
with IL-4 promote Th2 differentiation.  Keratinocytes produce chemokines including CCL17, CCL27, CCL11, CCL26.  Chemokines CCL17
and CCL27 recruit Th2 cells to the skin whereas CCL11 and CCL26 recruit eosinophils. TSLP activates DCs to prime naïve T helper cells to
Th2 cells and promote Th2 memory. The potentiation of the inflammatory response involves the complication of AD with bacterial infections.
Staphylococcal exotoxins activate LCs and IDECs to produce inflammatory mediators including IL-1β and TNF-α.  The mediators lead to
increased expression of chemokines which recruit T cells.  Th2 cytokines in AD decrease AMPs making lesions susceptible to infection.  PAF
receptor can also bind to LTA in addition to PAF.  LTA activated IDECs migrate to draining lymph nodes of skin to promote Th1 responses 
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permeability barrier may be a result of an altered lipid
composition, such as decreased ceramide, in the 
stratum corneum (SC).26 Ceramides are major water
retaining molecules present in the extracellular space
of the cornified envelope. During the process of 
cornification, the ceramide containing bilayer is 
covalently attached to various proteins on the 
extracellular surface of the cornified envelope.27 TEWL
levels have been shown to correlate with the content of
covalently bound ceramides.28 The 
mechanisms by which the ceramide content is altered
include the decreased activity of epidermal acid sphin-
gomyelinase (A-SMase) in lesional and non lesional
skin which correlates with reduced SC ceramide 
content and defects in permeability barrier.26 Recent
studies have demonstrated that stress, which is a
known exacerbator for AD, can have direct effects on
skin barrier properties. Reports have demonstrated that
insomniac psychologic stress affects epidermal cell prolif-
eration, impairs epidermal differentiation and reduces
the formation of lamellar bodies (LB) ultimately result-
ing in reduced synthesis of epidermal 
lipids such as cholesterol, fatty acid and ceramides.29
The abnormalities in both permeability barrier 
homeostasis and SC integrity induced by psychologic
stress may be mediated by increased endogenous 
glucocorticoids.30
The pathogenesis of AD may involve both
genetic and environmental factors. Several studies
now demonstrate that genetic mutations alone are not
sufficient to predispose to AD and the importance of
impaired epidermal barrier in patients with AD has
received increased attention.  Both the acute eczema-
tous lesions and uninvolved skin have impaired barrier
function. This process is believed to occur in two
phases, first by a genetic predisposition to synthesize
elevated levels of stratum corneum chymotryptic
enzyme (SCCE) which results in early degradation of
corneodesmosomes thereby damaging the skin barrier.31
Secondly, environmental effects due to application of
soap or long term topical corticosteroids may further
increase the production of this enzyme leading to
impaired epidermal function.  Exogenous proteases
from house dust mites and Staphylococcus aureus
may also impair the epidermal barrier.
AD has been demonstrated to show genetic
linkage to chromosome 1q21.32 The region on 
chromosome 1q21 contains the epidermal differentiation
complex (EDC) where a number of genes associated
with epidermal differentiation and barrier function
reside.33, 34 Recent reports have shown that two 
functional mutations in the epidermal differentiation
complex gene filaggrin (FLG) are strongly associated
with AD, the asthma often accompanying AD,35 and
also the common skin disorder ichthyosis vulgaris.36
The FLG gene encodes for a protein profilaggrin,
which becomes cleaved in the suprabasal 
keratinocytes to form the active protein filaggrin.
Filaggrin is associated with keratin intermediate 
filaments and allows them to be packed into bundles.
In the terminally differentiated keratinocytes, filaggrin
becomes cross-linked to the cornified cell envelope
resulting in an insoluble barrier in the stratum
corneum. Thus, filaggrin is necessary for the formation
and hydration of the skin barrier and protects the
organism against environmental agents.37 Studies to
date suggest FLG mutations predispose to extrinsic
but not intrinsic AD implicating that the skin barrier
defect is a key event in AD that can subsequently lead
to the development of secondary allergic symptoms
and respiratory atopy.38 It should be noted that in
addition to genetic FLG mutations, presumably the
amount of FLG can be regulated resulting in a func-
tional loss of the barrier properties of skin. 
TRIGGERS FOR ATOPIC DERMATITIS
A. Food and aeroallergens
Atopic dermatitis is commonly the first manifestation
of atopic disease.  As many as 75% of children with
severe AD will eventually develop asthma and/or allergic
rhinitis.39 The exact role however of allergen 
exposure in atopic dermatitis is controversial.40 Yet
allergic triggers such as allergens in food and 
environment have been shown to be associated with
the pathogenesis of AD.
The majority of IgE-mediated food reactions
that affect the skin are urticarial.  Therefore the ability
of foods to exacerbate AD has been questioned.41
There are now a number of well-controlled studies42
demonstrating an association between food ingestion
and the development of an eczematous rash in 
children with AD. Approximately 40% of children with
moderate to severe AD have a food allergy and 
ingestion of the offending food will exacerbate AD.43
The most common food allergy associated with AD is
hen egg. Dairy, wheat, soy and peanut allergy can also
exacerbate AD.44 Diagnosis of food allergy is still 
problematic as the presence of a positive food skin
prick test or positive serum IgE food assay does not
always correlate with clinical sensitivity.45 These data
have provided compelling arguments for food allergy
involvement in AD. Hence, the clinician must carefully
evaluate the impact of food avoidance on disease
severity.
House dust mite is the most well studied
aeroallergen.  The application of dust mite allergen
with a patch test will induce an eczematous lesion in
sensitized patients with AD. Numerous controlled
studies have not only shown an association between
aeroallergen exposure and exacerbation of AD but
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been shown to kill a broad range of microbes including
Staphylococcus aureus.64,65 Decreased expression of
human β-defensin 3 has been demonstrated in the
lesional skin of both extrinsic and intrinsic types of
AD.63,66,67 Neutralizing the Th2 cytokine mileu in AD
skin may lead to enhanced innate immune responses
against bacterial and viral pathogens.68 AD skin has
been reported to exhibit reduced expression of
antimicrobial genes due to a lack of proinflammatory
cytokines including TNF-α or IFN-γ important for
induction of anti-microbial peptides.69 The severity of
lesions is further enhanced by microbial products
including superantigens, lipoteichoic acid and 
peptidoglycan.70
IMMUNE MECHANISMS IN ATOPIC DERMATITIS
A. Effector cells
 T cells
Atopic dermatitis generally results from 
dysregulated Th2 biased immune responses to 
environmental and bacterial stimuli.71, 72 Recent studies
in acute and chronic lesions of AD patients have 
indicated the presence of Th2 cells secreting IL-4 in
early lesions and unaffected skin, with skewing to a
mixed Th1-Th2 profile or dominance of IFN-γ producing
Th1 cells in late lesions.50 Studies have further indicated
that acute T-cell infiltration in AD is associated with a
predominance of IL-4 and IL-13 expression while
chronic lesions reveal increased IL-5, GM-CSF, IL-12
and IFN-γ expression.73-75 In mouse models of trans-
genic and knockout mice, Th1 and Th2 cytokines are
well known to affect allergic skin inflammation.
Overexpression of the Th2 cytokine, IL-4 in the skin
has been shown to result in the manifestation of 
AD-like symptoms in mice.76 On the contrary, allergen
sensitized skin from mice deficient in IL-4 and IL-5 lack
eosinophils and the skin from IFN-γ-deficient mice
demonstrate decreased thickening of the dermis indi-
cating the importance of Th1 and Th2 cytokines in
AD.77 Other studies have indicated the importance of
Th2-cytokines, IL-4 and IL-13 at the onset of AD and IL-
5 at the later stages of AD.74 In addition to the Th1 and
Th2 subset of T cells, defects in T regulatory cells have
been implicated in the development of polyen-
docrinopathy X-linked syndrome involving hyper-IgE,
food allergy, and eczema.78 In a murine model of AD,
studies have suggested that invariant natural killer T
cells (iNKT) cells, γδ T cells and B cells are dispensable
in the development of allergic skin inflammation.79,80
 Antigen-presenting cells
Two distinct antigen presenting dendritic cells
(DCs) namely Langerhans cells (LCs) and inflammatory
dendritic epidermal cells (IDECs) have been implicated
in AD skin.81 LCs predominate at the initial phases of
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that appropriate avoidance measures can improve
AD.46, 47 Thus avoidance of food allergens and limiting
exposure to aeroallergens may help in reducing the
symptoms of AD.  
B. Infectious Triggers
Atopic dermatitis patients have increased 
susceptibility to bacterial, viral and fungal skin 
infections.16,48-50 Approximately, 90% of AD patients
demonstrate the presence of Staphylococcus aureus
in the lesions.51 The Staphylococcal exotoxins can
activate skin Langerhans cells and macrophages to
produce keratinocyte inflammatory mediators including
IL-1 and TNF-α.52 These mediators lead to increased
expression of endothelial cell adhesion receptors and
chemokines which can recruit T cells. The skin
endothelial cell adhesion receptor, E-selectin binds to
cutaneous lymphocyte associated antigen (CLA+) skin
homing memory T cells. CLA+ T cells are biased to
producing Th2 cytokines. Staphylococcal exotoxin
specific IgE antibodies in AD patients can bind to
basophils and mast cells to release histamine ultimately
leading to pruritic skin.53-55
The skin of AD patients is also susceptible to
viral skin infections following inoculation with 
vaccinia virus. Studies examining the role of Th2
cytokines, IL-4 and IL-13 in vaccinia virus infection
demonstrated increased vaccinia virus replication and
decreased expression of the human cathelicidin LL-37
(antimicrobial peptide) in AD skin.56 The mechanisms
underlying the above effects of increased vaccinia
virus replication by Th2 cytokines may involve subversion
of the innate immune responses to vaccinia virus via a
Stat6-dependent pathway. Further studies indicated
decreased expression of macrophage inflammatory
protein 3α (MIP-3α) in AD skin by Th2 cytokines.
Therefore it is suggested that neutralizing Th2
cytokines or increasing MIP-3α may reduce adverse
reactions in AD after smallpox vaccination.57
Atopic dermatitis patients, particularly those
with head and neck dermatitis, are often affected by a
fungal pathogen Malassezia furfur.58 The presence of
IgE antibodies against M. furfur in these patients has
been reported in patients with both extrinsic and
intrinsic types of AD.  Antifungal therapy has shown to
be promising in a subgroup of AD patients.59, 60
To combat the bacterial infections, the body
mounts innate immune responses via Toll like receptors
(TLRs), antimicrobial peptides (AMPs) or production
of proinflammatory cytokines. Antimicrobial peptides
play an important role in determining the susceptibility
to infection.61-63 A study involving cathelicidins and
human β-defensin 2 demonstrated a synergistic
antimicrobial effect to Staphylococcus aureus.61 A new
antimicrobial peptide namely, human β-defensin 3 has
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AD and prime naïve T cells to the Th2 type.82
Triggering of the FcεRI receptor on the surface of LCs
by allergens induces chemotactic signals and recruits
precursor cells of IDECs and T cells in vitro.
Engagement of FcγRI on IDECs further induces proin-
flammatory signals amplifying the immune response.81
Thus DCs expressing membrane IgE receptors play a
critical role in the amplification of allergen specific T
cell responses.  It has been reported that low numbers
of plasmacytoid DCs in the epidermal skin lesions of
AD patients allows them to be highly prone to viral
skin infections like herpes simplex-induced eczema
herpeticum.83
 Keratinocytes
Keratinocytes of AD patients exhibit an
increased propensity to produce cytokines and
chemokines, a phenomenon that plays a major role in
promoting and maintaining skin inflammation. The
well known cytokine thymic stromal lymphopoietin
(TSLP) produced by keratinocytes activates DCs which
in turn primes T cells to support the maintenance of
Th2 cells.84 Chemokines like RANTES are produced in
significant amounts following stimulation with TNF-α
and IFN-γ leading to increased recruitment of
eosinophils.85,86 Epidermal keratinocytes of AD lesions
also produce increased levels of GM-CSF.87, 88
Keratinocytes also express functional receptors
like CD14 and Toll-like receptor 4 (TLR4) and on stim-
ulation with lipopolysaccharides (LPS) can trigger pro-
inflammatory responses. In addition to secreting
cytokines and chemokines, the keratinocytes synthe-
size antimicrobial peptides on exposure to microor-
ganisms.89 Studies have implicated T cell mediated Fas-
mediated keratinocyte apoptosis to play an important
role in the development of eczematous lesions in AD.90
 Mast cells
Mast cells contribute significantly to the 
pathogenesis of AD. Cross-linkage of specific IgE recep-
tors on dermal mast cells provokes the release and synthe-
sis of a vast array of mediators.91, 92 Following their
recruitment and activation into the skin, eosinophils
are also thought to contribute relevantly to tissue dam-
age. Thus, a complex network of cytokines and
chemokines contributes to establishing a local milieu
that favors the permanence of inflammation in AD skin.
The importance of mast cells in controlling the
expression of IFN-γ and circulating IgE levels in a
model of allergen-induced skin inflammation was
studied in mast cell deficient mice (W/W(v)).93 In this
model W/W(v) mice were sensitized epicutaneously
with OVA (ovalbumin) and the results indicated com-
parable infiltration of mononuclear cells, T cells and
eosinophils between wild type controls and mast cell
deficient mice.  However, a significant upregulation of
IFN-γ in OVA sensitized skin and elevated total serum
IgE levels were observed in mast cell deficient mice in
comparison to wild-type controls. These results 
suggest that mast cells may regulate multiple aspects
of the immune response following epicutaneous sen-
sitization.
In addition to the role of mast cells in allergic
reactions, they are also involved in neuro-inflammato-
ry diseases which are worsened by stress.94 AD among
other inflammatory diseases has been reported to be
aggravated by psychological stress by trigerring pruri-
tis.  Mast cells are a key component of the stress
response in addition to nerve growth factor, corti-
cotrophin releasing hormone and substance P.
It is well documented that TSLP expression is
correlated to the pathogenesis of AD.  TSLP can stim-
ulate mast cells and dendritic cells to initiate the
innate allergic immune responses.95 In the latter phas-
es, TSLP activated DCs mediate the T cell dependent
adaptive phase of the allergic immune response.
 Eosinophils
Activated eosinophils in the peripheral blood
and skin lesions play an important role in the patho-
genesis of AD.96,97 Although, human eosinophils
express several chemokine receptors including CCR2,
CCR3 and CXCR4, most studies have indicated the
importance of CCR3 in the development of human AD
and mouse models of AD. The ligands associated with
CCR3 linked to the development of human AD
include CCL5, CCL11, CCL13 and CCL26. Further
studies have suggested RANTES also plays a role in
activation and chemotaxis of eosinophils.
Leptin, a pleiotropic adipocyte-derived cytokine
used in hypothalamic regulation of body weight and
modulation of immune response, has been proposed
to have a role in eosinophil survival and activation.98, 99
Leptin was shown to up-regulate cell surface expres-
sion of adhesion molecules ICAM-1 and CD18 and
suppress ICAM-3 and L-selectin on eosinophils.  It also
stimulated the release of IL-1β, IL-6, IL-8 and MCP-1
via differential intracellular signaling mechanisms.99
B. Effector cytokines and chemokines
Several studies have reported the initiation of
atopic skin lesions to be mediated by IL-4 producing
Th2 cells whereas chronic lesions may have a mixed
Th2 and Th1 coexistence or may be predominated by
Th1 cells alone.50, 74 The involvement of IL-4 and IL-13
in the initial phases and IL-5 in the later phases has
also been noted.74 Despite the clear association of
Th2 cytokines with AD, in several mouse models of
AD, allergic skin inflammation develops in the
absence of Th2 cells. Chronic AD is associated with
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Th1 like cytokines IL-12 and IL-18 and remodeling
cytokines including IL-11 and TGF-β1.100
IL-10 may also have a role in regulating allergic
skin inflammation. Reduced skin specific infiltration
of eosinophils and expression of IL-4, IL-5 and eotax-
in mRNA were observed in IL-10-/-mice sensitized epi-
cutaneously to OVA.101 In vitro stimulation of spleno-
cytes from sensitized IL-10-/- mice demonstrated sig-
nificant enhancement in the levels of IFN-γ concomi-
tant with reduced levels of IL-4, compared to wild
type mice.  Thus, IL-10 may modulate AD.
IL-31, a Th2 effector cytokine plays an essential
role in allergic skin inflammation, AD and allergic
asthma.102 The activity of IL-31 is mediated through a
heterodimeric receptor made up of IL-31RA and onco-
statin M receptor (OSMR)103 expressed on epidermal
keratinocytes and bronchial epithelial cells.104,105
Ligand stimulation of receptor expressing cells results
in increased expression of chemokines and cytokines
that potentiate allergic inflammation.  
Numerous chemokines including CCL1, CCL2,
CCL3, CCL4, CCL5, CCL1, CCL13, CCL18, CCL20,
CCL22, CCL26 and CCL27 have been implicated in the
pathogenesis of AD.70,106-117 CCL27 is a skin specific
chemokine made by keratinocytes following 
induction by TNF-α and IL-1β.108, 118 The CCL27-CCR10
interaction plays an important role in controlling
recruitment of memory T cells to the skin108 though
CCR4 has also been reported to play a role in this
process, and skin homing CLA+ memory T cells have
been shown to express CCR10 and CCR4.119 The CCR4
ligand, CCL17 is expressed by cutaneous venules and
may play a role in recruiting CCR4+ cells. However,
CCL18 is the most highly expressed ligand specific to
AD with levels in the lesional skin reported to be 100
fold higher than CCL17.115 The regulation of CCL18 by
allergen exposure and microbial products suggest a
crucial role for this chemokine in the initiation and
amplification of atopic skin inflammation.115,120
Further, CCL1-CCR8 mediated recruitment has been
shown to play a role in DC-T cell interactions at the
sites of atopic skin inflammation. Further work will
delineate whether targeting these molecules might
provide therapeutic benefit.
C. Lipid-derived mediators
Lipid-derived mediators include the
eicosanoids derived from arachidonic acid and
platelet-activating factor derived from glycerophos-
phocholines.  Arachidonic acid released from mem-
brane phospholipids can be metabolized by cyclooxy-
genase to form prostaglandins (PGs), and by 5-lipoxy-
genase to form leukotrienes (LTs).  The PGs, compris-
ing PGE2, PGD2, 6-ketoPGF1α, PGF2α, and thrombox-
ane A2 (TXA2), exhibit diverse pharmacological 
activities, including those related to inflammation,
reproduction, nociception, gastrointestinal protec-
tion, platelet aggregation, and renal blood flow and
vascular homeostasis.121, 122 Recent studies suggest that
cutaneous pruritus, one of the hallmarks of atopic
dermatitis, is regulated by PGs, especially PGD2.
Using NC/Nga mice, agonists of PGD2 inhibit, and
cyclooxygenase inhibitors have been reported to aug-
ment, skin pruritus.123 Though PGs negatively regulate
pruritus, studies demonstrating that cyclooxygenase
inhibitors block IL-10 production in keratinocytes as
well as other cell types suggest a complex role for
these lipid mediators.124
Leukotrienes consisting of LTB4, and the 
cysteinyl leukotrienes LTC4, LTD4 and LTE4 also have
significant proinflammatory effects.125 Cysteinyl
leukotrienes in particular through their ability to
induce bronchoconstriction and increased vascular
permeability, have been implicated in asthma.
Cysteinyl leukotriene receptor antagonists such as
monteleukast are effective for asthma, though do not
appear to be useful for acute flares.  Monteleukast has
been also found to be mildly effective in atopic der-
matitis.126
Platelet-activating factor (1-alkyl-2-acetyl-glyc-
erophosphocholine; PAF) is a lipid mediator usually
produced concomitantly with eicosanoids.  Several
lines of evidence suggest involvement of PAF in
inflammatory skin diseases, especially atopic dermati-
tis.  First, PAF has been measured in urticarial-like
eruptions, including cold urticaria and bullous pem-
phigoid.127, 128 Second, intradermal injection of PAF
results in an urticarial wheal and flare reaction.128, 129 It
should be noted that intradermal injection of PAF into
atopic dermatitis patients resulted in enhanced reac-
tions with increased numbers of eosinophils in com-
parison to non-atopic counterparts.129 Moreover, the
wheal and flare responses to platelet activating factor
(PAF) or histamine, and the ultrastructural effects of
PAF are increased in the skin of atopic subjects 
compared to normal subjects.  Third, the lack of func-
tional serum PAF acetylhydrolase, which catalyzes
hydrolysis of PAF and short-chained sn-2 GPC, has
been linked to an exacerbated asthma phenotype in
the approximately 4% of the Japanese population with
homozygous mutations.130 
Finally, PAF stimulates the production of the
anti-inflammatory cytokine IL-10 in epidermal and
other cell types.124 Of significance, the PAF receptor
appears to be able to bind to ligands other than PAF.
These ligands include oxidatively modified 
glycerophosphocholines as well as bacterial products
including lipoteichoic acid.131, 132 The ability of the PAF
receptor to respond to bacterial products could pro-
vide one mechanism by which bacterial infection can
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serve as a trigger for worsening of atopic dermatitis
(Figure 2).  PAF receptor antagonists are not routinely
available, but rupatadine, a novel compound with
both H1 antihistamine and PAF receptor antagonistic
effects, has been shown to have efficacy in allergic 
disorders including allergic rhinitis.133 
VI. Genetic susceptibility
Atopic dermatitis is recognized as a multifactorial
heterogeneous genetic disease known to occur as a
result of genetic interactions with environmental 
factors.  Around 80% of eczema developing in chil-
dren is atopic, characterized by allergen specific IgE
and high total IgE in their sera.  Twin studies of AD
demonstrated concordance rates of 0.72-0.86 in
monozygotic, and 0.21-0.23 in dizygotic twin
pairs.134  Total serum IgE levels show a heritability of
50%.135-137 These studies indicate the importance of
genetic components in AD.
Association of AD with other atopic conditions
such as asthma and allergic rhinitis implicate a genetic
correlation between these conditions as evidenced by
cross phenotype familial clustering.138  Functional
polymorphisms of the genes and their association with
disease may provide novel mechanisms for the patho-
genesis of the disease.  Various approaches underlying
the identification of genes are discussed below.
A. Genome wide screens 
In studies of large families, genetic polymor-
phisms are mapped to discrete chromosomal regions
and genetic regions associated with disease are iden-
tified.  The linkage regions may contain several dis-
ease associated genes.  Genome screens have identi-
fied at least 4 regions of genetic linkage to AD on
chromosomes 1q, 3q, 3p and 17q.32,139-141 Other
mapped loci using composite phenotypes of AD and
asthma combined have shown genetic linkage to
chromosome 20p.32  Composite phenotypes for AD
with increased total serum IgE (16q)32 and allergen
specific IgE (3p, 4p, 18q)140 have also been reported.
Overlap of some of these loci with psoriasis (1q, 3q,
17q, 20p)32 or asthma (13q,142 20p32) has been
demonstrated.
B. Candidate gene studies
Candidate gene studies determine correlations
between phenotype and genotype at 1 or more poly-
morphic loci within a gene of interest.  Candidate
genes for AD include FLG, CTLA4, TLR2, TLR9, IRF2,
CD14, GM-CSF, IL-13, IL-4, SPINK5, CARD4, FcεRIβ, IL-
18, TIM1, PHF11, MCC, RANTES, Eotaxin, TGFβ1,
SCCE, CARD15, GSTT1.138 A brief description for some
of the genes is outlined below.
a. FcεRIβ
FcεRIβ is encoded by a single gene, MS4A2 on
chromosome 11q12-13, a region demonstrating linkage
to atopy.143, 144 Polymorphisms in this gene have shown
linkage with different atopy phenotypes.145-147
Moreover, an excessive transmission of maternal
FcεRIβ has been demonstrated in AD patients.148
b. RANTES and Eotaxin1
RANTES encoded by CCL5 and Eotaxin 1
encoded by CCL11 are located on chromosome 17
next to an AD linked region.  Polymorphisms in the
CCL5 promoter region have been shown to correlate
with increased levels of RANTES in AD patients.149, 150
Similarly polymorphisms in CCL11 promoter region
are associated with enhanced total serum IgE in AD
patients.150
c. Cytokine gene cluster
The cluster located on chromosome 5q31-33
comprises linked genes including IL3, IL4, IL5, IL9,
IL12, IL13, GM-CSF, CD14 antigen, T cell immunoglob-
ulin mucin domain (TIM-1) and SPINK5.138 Mutations
in the gene encoding SPINK5 are reported to cause
Netherton’s disease, a rare recessive disorder charac-
terized by generalized congenital erythroderma.151, 152
Further studies also demonstrated variants of SPINK5
to modify the risk of development of AD, asthma and
increased serum IgE levels.153-156 Several of the
cytokine cluster genes have been associated with AD
and total IgE levels.
d. Epidermal differentiation complex
AD shows genetic linkage to chromosome 1q21
which contains the epidermal differentiation complex
(EDC).  This complex is comprised of genes and gene
families expressed in the terminally differentiating
epithelium.32 Gene families in the EDC include the
S100 calcium binding proteins, small proline rich pro-
teins and late expressed cornified envelope proteins.
The single copy genes in EDC include trichohyalin,
repetin, loricrin, filaggrin and involucrin. Recent studies
have demonstrated that two functional mutations in
the gene encoding filaggrin (FLG) are strong risk fac-
tors for AD and asthma in European populations.35
Other studies demonstrated that these mutations
result in an extrinsic AD in patients suggesting that the
skin barrier defect precedes the development of aller-
gic sensitization in AD.157 Since FLG mutations have
not been commonly described in other non European
populations, studies have analyzed mutations in other
ancestral groups to determine the contribution of FLG
mutations to AD pathogenesis worldwide.158 In this
regard, two novel FLG mutations reported in Japanese
IV patients have recently been associated with AD.159  It
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is also reported that half of Irish AD cases carry FLG
null mutations.160 The role of other EDC genes in the
pathogenesis of AD needs to be explored further.
TRANSLATING LESSONS FROM LAB TO CLINIC
The treatment of AD entails education of the
patient and family.  Given the heterogeneity of this dis-
order, an individualized treatment regimen is essen-
tial.  The family and patient need to understand that
AD is a chronic disease with exacerbations due often
to exogenous environmental factors and psychologi-
cal factors.  Molecular and immunological studies that
have begun to illuminate the underlying pathogenic
mechanisms of AD have impacted therapy.  Figure 2
and Table 1 outline therapeutic clinical correlations of
AD pathogenesis.  These new “therapies” can be divid-
ed into those impacting the barrier abnormalities, and
those affecting the immune dysregulation, though the
two are certainly intertwined.  
A. Barrier Restorative Creams
The recent discovery of filaggrin mutations
associated with a significant number of AD cases have
confirmed the importance of barrier dysfunction in
this enigmatic disorder.  To treat the dry skin associat-
ed with AD, most clinicians recommend daily baths,
followed by an occlusive lubricant to retain the water
absorbed by the stratum corneum.  Use of emollient
creams during the day is also helpful in fighting the
increased TEWL seen in many AD patients.  
Several topical barrier creams have become
available for use in the management of AD.  These
physiologic moisturizers can be divided into three cat-
egories; the ceramide-dominant agents Cera-Ve,
TriCeramTM and EpiCeram; Mimyx, which contains the
fatty acid palmitamide; and AtopiclairTM cream contain-
ing the antiinflammatory molecule glycyrrhetinic acid,
telmesteine, shea butter, caprylol glycine, and
hyaluronic acid in a hydrolipidic base.  AtopiclairTM has
been shown to promote some modest improvement in
patients with mild- to moderate AD. The physiological
based ceramide-containing cream TriCeramTM has been
shown to result in significant improvement in child-
hood AD, both in clinical score as well as improved
barrier function.161 Other reports also demonstrate effi-
cacy of other ceramide-dominant agents.  
B. Reduction of allergic triggers
If investigations reveal the presence of allergies
in the AD patient, avoidance of the allergic triggers is
Clinical correlations of recent developments in the pathogenesis of atopic dermatitis 65
CHART 1: Therapeutic clinical correlations of atopic dermatitis pathogenesis  
Clinical Disease Component Pathogenesis Treatment Strategy
Dry skin Barrier disruption and increased Daily baths, with mild/absent soap,
TEWL associated with genetic or lubrication of skin.  Barrier restorative 
creams. Avoiding irritants and 
psychological stress
functional FLG mutations 
or other causes
Seborrheic dermatitis-like Allergies/hypersensitivity Antifungals, selenium either in shampoo
lesions to yeasts such as M. Furfur. or cream vehicle
Food/airborn allergies IgE directed against foods Identification of specific allergens and 
avoidance; use of dietician to assist in 
education.  Chronic H-1 antihistamines.  
Consideration of specific immunotherapy 
or immunosuppressive therapy  
(e.g., azathioprine, cyclosporine, 
mycophenolic acid) for short period 
of time.
Infected skin lesions Infection with S. aureus or Treat active infections; avoid potential
Group A. streptococcus fomites such as sponges in bath, toys, etc.
Topical antibiotic treatment of carriage of 
nares, umbilicus, anus, fingernails.  
Baths with antiseptic including dilute bleach.
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by far the optimal treatment strategy. If this is 
problematic, other potential therapies/strategies are
potentially available and are listed below. 
 Anti-IgE therapy
Omalizumab (Xolair, Novartis, East Hanover,NJ)
is a recombinant monoclonal antibody to IgE. It is cur-
rently approved for the treatment of asthma in
patients greater than 12 years of age with poorly con-
trolled atopic asthma and IgE levels < 700 IU/ml.
Patients with AD often have significant elevation of
serum IgE. There are a few case reports of improve-
ment in AD with omalizumab.162 However given the
cost and lack of controlled trials it currently can not
be recommended for treatment.
 Specific Immunotherapy (SIT)
SIT is allergen specific desensitization given by
subcutaneous injection (SCIT) or orally (SLIT).  Two
controlled SCIT studies for dust mite allergic patients
with AD have been published.163,164 Long-term treat-
ment with high dose SCIT produced statistically signif-
icant improvement in AD in both groups.  One con-
trolled SLIT study has shown skin improvement in
dust mite allergic children with AD.165 SLIT is current-
ly not approved for use in the United States.
C. Antimicrobial agents in the reduction of
Infectious triggers
a. Yeasts
Based on the reports that demonstrate abnormal
cutaneous reactions and IgE antibodies to Malassezia
yeasts in some patients with AD, especially those with sig-
nificant head and neck involvement that can somewhat
resemble the distribution of seborrheic dermatitis, sever-
al reports have demonstrated effectiveness of topical anti-
fungals as part of the treatment regimen.166 In particular,
a recent study demonstrated the effectiveness of
ciclopiroxolamine in a subgroup of AD patients with IgE
antibodies directed against mallasezia yeast.167 It should
be noted that that many anti-fungals, including ciclopirox-
olamine exert anti-inflammatory, as well as antimicrobial
effects.168 Thus, it is not clear whether the reported
improvement was due to the eradication of yeasts which
serve as a potential immune stimulus or a direct anti-
inflammatory effect.  
b. Bacteria
Bacterial superinfection is a known trigger for
worsening AD.51 Bacteria, especially Staphylococcus
aureus, can be cultured from the majority of AD
patients. Thus, clinicians experienced in AD 
treatment are vigilant in regards to both looking for
and treating secondary infections in AD patients.  The
usual treatment for secondary bacterial infection of
AD consists of oral antibiotics, as well as topical antibi-
otics.  Unfortunately, the chronic use of antibiotics can
be associated with bacterial resistance, and increased
numbers of methicillin-resistant staphylococcal
strains are emerging.169 A new antibiotic, retapamulin,
which is a member of the pleuromutilin class of antibi-
otics, has been shown to be as effective topically in
infected AD patients as oral antibiotic cephalexin.170  At
this time, there have no reports of bacterial resistance
to retapamulin.171
D. Calcineurin Inhibitors
Topical corticosteroids have been the mainstay
of AD treatment.  The regimen used most commonly
by the authors is a mid-potency topical corticosteroid
ointment for thickened areas of dermatitis on body,
with weaker non-fluorinated corticosteroids for larger
areas, face, or maintenance.  Though effective, their
use is limited by side effects which can include inhibi-
tion of barrier function, thinning of skin and resultant
striae, as well as acneiform eruptions.172 Systemic
absorption of glucocorticosteroids can cause adrenal
suppression in young children due to their higher
body surface area-to-weight ratios.  Although these
adverse effects are usually avoidable by prudent use of
corticosteroids, these side effects have made it desir-
able to have effective non-steroidal antinflammatory
agents for topical use in AD.
Calcineurin inhibitors (pimecrolimus, tacrolimus)
are effective topical agents that have been demonstrated
to be effective in AD.  Through their ability to interrupt
calcineurin pathways, they have potent effects on 
T cells.  Recent studies indicate they also have
immunomodulatory effects on other cell types impor-
tant in AD including dendritic cells and mast cells.173,174
Given the large size of these molecules, there is very 
little penetration in normal skin, unlike active AD
lesions characterized by defective barrier properties.
Consistent with this, some of the first reports demon-
strated low levels of tacrolimus in blood at the begin-
ning of therapy, which then were much lower as the
patient improved.175   Other side effects include transient
burning and stinging, seen more often with tacrolimus
over pimecrolimus.  These effects can be lessened by
refrigerating the medicine, and concomitant use of a
topical steroid.
The rather selective effects of these agents results in
a better safety profile. There are recent concerns about pos-
sible risk of malignancy associated with long-term use of
these agents.  In March, 2005, the US Food and Drug
Administration (FDA) issued a public health advisory
regarding the potential cancer risk from the use of
tacrolimus and pimecrolimus topical preparations.  This
advisory was historical as it was not based upon data indi-
cating an increase in cancers associated with the topical use
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of calcineurin inhibitors, but theoretical concerns as long
term use of systemic calcineurin inhibitors (eg, for organ
transplant patients) is known to result in increased skin
cancers.  Thus, the FDA recommended that these agents
should be reserved for patients who have failed other ther-
apies.  These concerns have resulted in a “black box warn-
ing” of possible cancer risk for the use of these agents. 
Though the FDA “black box warning” is present
for these agents, a nested case-control study examining
AD patients following exposure to topical calcineurin
inhibitors found no increased risk of lymphoma, unlike
systemic exposure to these agents.176 A scientific con-
sensus conference convened by the American Academy
of Dermatology concluded there is no causal proof that
topical calcineurin inhibitors cause lymphomas or non-
melanoma skin cancers.  However, the prudent use of
these agents is recommended, especially minimal use
as second-line agents for recalcitrant AD.
CONCLUSION  
Atopic dermatitis is a significant health problem
in Western society.  While AD is not life threatening, it
poses a chronic problem that impacts affected individ-
uals and their families both emotionally and financial-
ly.  The pathogenesis of AD is still not well understood,
but clearly involves the culmination of altered barrier
function of the skin, increased exposure of innate
immune cells to allergens, and the sensitization of T
cells that are primed to secrete Th2 cytokines, which
subsequently potentiate the local inflammatory
response (Figure 2). Microbial products, and the
immune response to pathogens can further exacerbate
allergic inflammation (Figure 2). Animal models have
defined some of the cell types and mediators involved
in the development of AD.  These cells and mediators
have been verified both biologically and genetically to
be important in patient populations.  As more aspects
of allergic inflammation have been revealed, therapies
have become directed to interfering with local immune
function and focus less on generalized immunosup-
pression. Ongoing studies in patients and animal models
will uncover additional details of disease that should
have a significant impact on diagnosis, treatment and
prevention of atopic dermatitis.                               
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